Evidence map›Paper›PMID 26092119›Full record

ArticleDisease models & mechanisms2015

A state of reversible compensated ventricular dysfunction precedes pathological remodelling in response to cardiomyocyte-specific activity of angiotensin II type-1 receptor in mice.

Georgia A Frentzou, Mark J Drinkhill, Neil A Turner, Stephen G Ball, Justin F X Ainscough

Open access · goldAbstract read
In one paragraph

Article in Disease models & mechanisms, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Cardiac fibroblast-specific p38α MAP kinase promotes cardiac hypertrophy via a putative paracrine interleukin-6 signaling mechanism.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2018
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Georgia A FrentzouLeeds Institute of Cardiovascular & Metabolic Medicine, and Multidisciplinary Cardiovascular Research Centre, University of Leeds, Leeds LS2 9JT, UK alkistis_frentzou@hotmail.co.uk justin.ainscough@york.ac.uk.
Mark J DrinkhillLeeds Institute of Cardiovascular & Metabolic Medicine, and Multidisciplinary Cardiovascular Research Centre, University of Leeds, Leeds LS2 9JT, UK.
Neil A TurnerLeeds Institute of Cardiovascular & Metabolic Medicine, and Multidisciplinary Cardiovascular Research Centre, University of Leeds, Leeds LS2 9JT, UK.
Stephen G BallLeeds Institute of Cardiovascular & Metabolic Medicine, and Multidisciplinary Cardiovascular Research Centre, University of Leeds, Leeds LS2 9JT, UK.
Justin F X AinscoughLeeds Institute of Cardiovascular & Metabolic Medicine, and Multidisciplinary Cardiovascular Research Centre, University of Leeds, Leeds LS2 9JT, UK alkistis_frentzou@hotmail.co.uk justin.ainscough@york.ac.uk.
University of Leeds · GB

Funding

British Heart Foundation PG/09/055
6 · The paper itself

Abstract

Cardiac dysfunction is commonly associated with high-blood-pressure-induced cardiomyocyte hypertrophy, in response to aberrant renin-angiotensin system (RAS) activity. Ensuing pathological remodelling promotes cardiomyocyte death and cardiac fibroblast activation, leading to cardiac fibrosis. The initiating cellular mechanisms that underlie this progressive disease are poorly understood. We previously reported a conditional mouse model in which a human angiotensin II type-I receptor transgene (HART) was expressed in differentiated cardiomyocytes after they had fully matured, but not during development. Twelve-month-old HART mice exhibited ventricular dysfunction and cardiomyocyte hypertrophy with interstitial fibrosis following full receptor stimulation, without affecting blood pressure. Here, we show that chronic HART activity in young adult mice causes ventricular dysfunction without hypertrophy, fibrosis or cardiomyocyte death. Dysfunction correlated with reduced expression of pro-hypertrophy markers and increased expression of pro-angiogenic markers in the cardiomyocytes experiencing increased receptor load. This stimulates responsive changes in closely associated non-myocyte cells, including the downregulation of pro-angiogenic genes, a dampened inflammatory response and upregulation of Tgfβ. Importantly, this state of compensated dysfunction was reversible. Furthermore, increased stimulation of the receptors on the cardiomyocytes caused a switch in the secondary response from the non-myocyte cells. Progressive cardiac remodelling was stimulated through hypertrophy and death of individual cardiomyocytes, with infiltration, proliferation and activation of fibroblast and inflammatory cells, leading to increased angiogenic and inflammatory signalling. Together, these data demonstrate that a state of pre-hypertrophic compensated dysfunction can exist in affected individuals before common markers of heart disease are detectable. The data also suggest that there is an initial response from the housekeeping cells of the heart to signals emanating from distressed neighbouring cardiomyocytes to suppress those changes most commonly associated with progressive heart disease. We suggest that the reversible nature of this state of compensated dysfunction presents an ideal window of opportunity for personalised therapeutic intervention.

Indexed as

Ventricular RemodelingAngiotensin IIAnimalsCell DeathFibrosisGene Expression ProfilingGene Expression RegulationHeart Function TestsHumansHypertrophy, Left VentricularMacrophagesMaleMiceModels, CardiovascularMyocytes, CardiacReceptor, Angiotensin, Type 1Angiotensin IIReceptor, Angiotensin, Type 1Cardiac hypertrophyConditional transgenic mouseDysfunctionFibrosisRemodellingRenin angiotensin system

Identifiers

PMID26092119
PMCPMC4527284
OpenAlexW2167211216

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.